ImmunityBio, Inc. (IBRX) — Stock Price, Chart & Analysis
ImmunityBio, Inc. (IBRX) is a Healthcare stock currently trading at $8.46, up 21.03% on the day. It carries a market capitalization of $9.85B. Over the past 52 weeks, IBRX has traded between $1.95 and $12.43. ImmunityBio, Inc. does not currently pay a regular dividend. View the live IBRX chart, technical opinion, analyst ratings, fundamentals and latest news below.
ImmunityBio, Inc. (IBRX) key data
| Price | $8.46 |
| Change (today) | +21.03% |
| Previous close | $6.99 |
| Market cap | $9.85B |
| EPS (TTM) | $-1.04 |
| 52-week high | $12.43 |
| 52-week low | $1.95 |
| Beta | 0.14 |
| Avg. volume | 10.18M |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about ImmunityBio, Inc. (IBRX)
How much does one share of ImmunityBio, Inc. cost?
As of the latest update, one share of ImmunityBio, Inc. (IBRX) trades at $8.46 (+21.03% today).
What is ImmunityBio, Inc.'s market cap?
ImmunityBio, Inc. has a market capitalization of approximately $9.85B.
What is ImmunityBio, Inc.'s earnings per share (EPS)?
ImmunityBio, Inc.'s trailing twelve-month EPS is $-1.04.
Does ImmunityBio, Inc. pay a dividend?
ImmunityBio, Inc. does not currently pay a regular dividend.
What is ImmunityBio, Inc.'s 52-week trading range?
Over the past year, IBRX has traded between $1.95 and $12.43.
What is the analyst price target for ImmunityBio, Inc.?
The mean analyst price target for ImmunityBio, Inc. is $12.75. This is informational only and not investment advice.
Latest ImmunityBio, Inc. (IBRX) news
- ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%News · Sep 23, 2026
- Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation ModeNews · Sep 21, 2026
- ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?News · Sep 18, 2026
- SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 DealsNews · Sep 15, 2026
- IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy BetNews · Sep 14, 2026
- SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On DeckNews · Sep 14, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live IBRX dashboard…